William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report issued on Tuesday,RTT News reports. Other research analysts have also ...

BTIG analyst Julian Harrison reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) today and set a price target of $4.00. The ...

In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report). The ...

Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's ...

Nektar Therapeutics (NKTR) has been beaten down lately with too much selling pressure. While the stock has lost 38.5% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Nektar Therapeutics’s NKTR share price has surged by 22.00%, which has investors questioning if this is right time to sell.

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...

Shares of Nektar Therapeutics (NKTR) have been struggling lately and have lost 11.5% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could ...

SAN FRANCISCO and NEW YORK - Nektar Therapeutics (NASDAQ: NASDAQ:NKTR), a clinical-stage biotechnology company currently trading at $0.93 per share with a market capitalization of $173 million ...

TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics ...